RJA
BPMC

Raymond James & Associates’s Blueprint Medicines BPMC Stock Holding History

Raymond James & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.56M Buy
16,898
+3,348
+25% +$333K ﹤0.01% 2392
2024
Q2 		$1.46M Buy
13,550
+4,215
+45% +$422K ﹤0.01% 2352
2024
Q1 		$886K Sell
9,335
-1,357
-13% -$116K ﹤0.01% 2669
2023
Q4 		$986K Sell
10,692
-8,755
-45% -$567K ﹤0.01% 2526
2023
Q3 		$977K Sell
19,447
-10,288
-35% -$550K ﹤0.01% 2469
2023
Q2 		$1.88M Buy
29,735
+14,639
+97% +$796K ﹤0.01% 2095
2023
Q1 		$679K Buy
15,096
+819
+6% +$36.9K ﹤0.01% 2723
2022
Q4 		$625K Sell
14,277
-17,156
-55% -$823K ﹤0.01% 2736
2022
Q3 		$2.07M Buy
31,433
+2,551
+9% +$164K ﹤0.01% 1938
2022
Q2 		$1.46M Sell
28,882
-2,683
-8% -$157K ﹤0.01% 2202
2022
Q1 		$2.02M Buy
31,565
+4,945
+19% +$355K ﹤0.01% 2123
2021
Q4 		$2.85M Buy
26,620
+6,520
+32% +$682K ﹤0.01% 1925
2021
Q3 		$2.07M Buy
20,100
+2,087
+12% +$194K ﹤0.01% 2076
2021
Q2 		$1.58M Sell
18,013
-234
-1% -$21.4K ﹤0.01% 2270
2021
Q1 		$1.77M Sell
18,247
-15,944
-47% -$1.59M ﹤0.01% 2101
2020
Q4 		$3.83M Sell
34,191
-3,787
-10% -$399K ﹤0.01% 1481
2020
Q3 		$3.52M Buy
37,978
+6,025
+19% +$464K ﹤0.01% 1412
2020
Q2 		$2.49M Buy
31,953
+2,391
+8% +$162K ﹤0.01% 1593
2020
Q1 		$1.73M Buy
29,562
+5,248
+22% +$338K ﹤0.01% 1656
2019
Q4 		$1.95M Buy
24,314
+15,546
+177% +$1.16M ﹤0.01% 1839
2019
Q3 		$644K Buy
8,768
+741
+9% +$64.1K ﹤0.01% 2484
2019
Q2 		$757K Sell
8,027
-2,002
-20% -$165K ﹤0.01% 2377
2019
Q1 		$803K Sell
10,029
-638
-6% -$47.1K ﹤0.01% 2332
2018
Q4 		$575K Sell
10,667
-69
-0.6% -$4.19K ﹤0.01% 2458
2018
Q3 		$838K Buy
+10,736
New +$746K ﹤0.01% 2366
2018
Q2 		– Sell
-2,556
Closed -$234K – 3597
2018
Q1 		$234K Sell
2,556
-448
-15% -$38.6K ﹤0.01% 3051
2017
Q4 		$227K Sell
3,004
-133
-4% -$9.36K ﹤0.01% 2985
2017
Q3 		$219K Buy
+3,137
New +$168K ﹤0.01% 2986

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James & Associates's BPMC Position: Q3 2024 in Review

Raymond James & Associates increased its Blueprint Medicines (BPMC) stake by 25% in Q3 2024, buying an estimated $333K and bringing the position to 16,898 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2392.

Raymond James & Associates first reported a position in BPMC in Q3 2017 and has held it in 28 quarters since. The position peaked at $3.83M in Q4 2020. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Raymond James & Associates held 16,898 shares of Blueprint Medicines worth $1.56M as of Q3 2024.
  • Raymond James & Associates bought 3,348 Blueprint Medicines shares in Q3 2024, an estimated $333K.
  • Blueprint Medicines made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2392 holding.
  • Raymond James & Associates first reported a position in Blueprint Medicines in Q3 2017 and has held it in 28 quarters since.
  • Raymond James & Associates's Blueprint Medicines position peaked at $3.83M in Q4 2020.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.